Risk factors and clinical features for post-transplant thoracic air-leak syndrome in adult patients receiving allogeneic haematopoietic stem cell transplantation

被引:0
|
作者
Yao-Chung Liu
Yi-Hsin Chou
Po-Shen Ko
Hao-Yuan Wang
Nai-Wen Fan
Chia-Jen Liu
Liang-Tsai Hsiao
Sheng-Hsuan Chien
Tzeon-Jye Chiou
Jin-Hwang Liu
Jyh-Pyng Gau
机构
[1] Taipei Veterans General Hospital,Division of Haematology, Department of Medicine
[2] National Yang-Ming University,Faculty of Medicine
[3] Taipei Veterans General Hospital,Department of Ophthalmology
[4] Taipei Veterans General Hospital,Division of Transfusion Medicine, Department of Medicine
[5] Taipei Tzu Chi Hospital,Division of Haematology and Oncology, Department of Medicine
[6] Buddhist Tzu Chi Medical Foundation,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Post-transplant thoracic air-leak syndrome (ALS) is rare but potentially life-threatening in patients receiving allogeneic haematopoietic stem cell transplantation (HSCT). Nevertheless, papers on thoracic ALS are limited, and this complication remains largely unknown. We reviewed 423 adult patients undergoing allogeneic HSCT from 2003 to 2014. Risk factors, clinical features and survival for thoracic ALS were collected and analysed. Thirteen out of 423 patients (3.1%) developed post-transplant thoracic ALS, including two ALS patients in the early phase. The median age at HSCT was 33 years among 13 patients with thoracic ALS. Male patients were predominant (69%). The median onset time was 253 days (range: 40–2680) after HSCT. Multivariate analysis revealed that grade III–IV acute graft-versus-host disease (GVHD) (p = 0.017), extensive chronic GVHD (cGVHD) (p = 0.019) and prior history of pulmonary invasive fungal infection (p = 0.007) were significant risk factors for thoracic ALS. In patients with cGVHD, those with thoracic ALS had a significantly worse survival than those without thoracic ALS (p = 0.04). Currently, published data analysing and exploring post-transplant thoracic ALS are limited. Our study employed a large patient cohort and determined the risk factors and clinical features for post-transplant thoracic ALS.
引用
收藏
相关论文
共 50 条
  • [21] Post-transplant flow cytometry MRD predicts relapse in AML and high risk MDS patients treated with allogeneic haematopoietic stem cell transplant
    Wood, H.
    Sanchez, K.
    Potter, V.
    Kulasekararaj, A.
    Yallop, D.
    Kassam, S.
    Ireland, R.
    Mufti, G.
    Dunlop, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 153 - 154
  • [22] Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome
    Herrity, Elizabeth Kathryn
    Alfaro, Tommy
    Pereira, Mariana Pinto
    Novitzky-Basso, Igor
    Lam, Wilson
    Pasic, Ivan
    Michelis, Fotios
    Law, Arjun D.
    Viswabandya, Auro
    Smith, Adam
    Tierens, Anne Maria
    Gerbitz, Armin
    Kumar, Rajat
    Mattsson, Jonas
    Kim, Dennis D. H.
    BLOOD, 2023, 142
  • [23] Influence of Pre-Transplant Cytomegalovirus (CMV) Serostatus on Post-Transplant Viral Reactivation after Allogeneic Stem Cell Transplantation in Patients Receiving Post-Transplant Cyclophosphamide for Gvhd Prophylaxis
    Paluri, Ravi K.
    Shelton, Racquel
    Gazi, Melissa
    Lamb, Lawrence S.
    Saad, Ayman
    Salzman, Donna
    Di Stasi, Antonio
    Mineishi, Shin
    BLOOD, 2014, 124 (21)
  • [24] DONOR AND RECIPIENT STR ANALYSIS BEFORE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: POSSIBLE CORRELATION WITH POST-TRANSPLANT OUTCOME
    Giammarco, S.
    Bellesi, S.
    Metafuni, E.
    Sora, F.
    Laurenti, L.
    Sica, S.
    Leone, G.
    Chiusolo, P.
    HAEMATOLOGICA, 2013, 98 : 155 - 155
  • [25] Features and outcome of early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantatioN
    Dulery, Remy
    Mohty, Razan
    Labopin, Myriam
    Sestili, Simona
    Malard, Florent
    Brissot, Eolia
    Battipaglia, Giorgia
    Mediavilla, Clemence
    Banet, Anne
    Van de Wyngaert, Zoe
    Paviglianiti, Annalisa
    Belhocine, Ramdane
    Isnard, Francoise
    Lapusan, Simona
    Adaeva, Rosa
    Vekhoff, Anne
    Ledraa, Tounes
    Legrand, Ollivier
    Cohen, Ariel
    Bonnin, Agnes
    Ederhy, Stephane
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2019, 54 : 69 - 70
  • [26] Tempo of neutrophil recovery and the definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation (HSCT) in patients not receiving growth factors post-transplant
    Naik, P
    Verma, A
    Pedicano, J
    Gordon, L
    Singhal, S
    Tallman, M
    Williams, S
    Winter, J
    Mehta, J
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 84 - 84
  • [27] Incidence and risk factors for hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation
    Gomez Hernando, M.
    Pedraza, A.
    Quintana, L.
    Carcelero, E.
    Riu, G.
    Monge, I.
    Domenech, A.
    Solano, M. T.
    Suarez-Lledo, M.
    Martinez-Cibrian, N.
    Rosinol, L.
    Gutierrez-Garcia, G.
    Carreras, E.
    Esteve, J.
    Urbano-Ispizua, A.
    Fernandez Aviles, F.
    Martinez, C.
    Rovira, M.
    Salas, M. Q.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 193 - 193
  • [28] OVERVIEW OF POST-TRANSPLANT MONITORING IN PATIENTS AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Cechova, Hana
    Pegova, Kristyna
    Pavlatova, Lucie
    Zizkova, Radka
    Hrabakova, Pavla
    Prerovska, Renata
    Stankova, Martina
    Brezinova, Dagmar
    HLA, 2018, 91 (05) : 403 - 404
  • [29] Risk factors for haemorrhagic cystitis in β thalassemic patients undergoing allogeneic haematopoietic stem cell transplant
    Orofino, M. G.
    Origa, R.
    Piroddi, A.
    Addari, M. C.
    Rizzo, F.
    Vacca, A.
    Piras, E.
    La Nasa, G.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S351 - S351
  • [30] Post-transplant immune reconstitution after allogeneic stem cell transplantation in paediatric patients with high-risk leukaemia
    Rigatou, E.
    Gumy-Pause, F.
    Mattiello, V.
    Chalandon, Y.
    Ansari, M.
    Ozsahin, H.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S149 - S150